Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Operating Leases (2019 - 2026)

Intellia Therapeutics has reported Operating Leases over the past 8 years, most recently at $61.4 million for Q1 2026.

  • Quarterly Operating Leases fell 23.72% to $61.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $61.4 million through Mar 2026, down 23.72% year-over-year, with the annual reading at $66.8 million for FY2025, 64.81% down from the prior year.
  • Operating Leases was $61.4 million for Q1 2026 at Intellia Therapeutics, down from $66.8 million in the prior quarter.
  • Over five years, Operating Leases peaked at $190.0 million in Q4 2024 and troughed at $60.0 million in Q2 2022.
  • The 5-year median for Operating Leases is $84.1 million (2022), against an average of $90.6 million.
  • Year-over-year, Operating Leases surged 96.34% in 2024 and then tumbled 64.81% in 2025.
  • A 5-year view of Operating Leases shows it stood at $114.0 million in 2022, then fell by 15.15% to $96.7 million in 2023, then skyrocketed by 96.34% to $190.0 million in 2024, then tumbled by 64.81% to $66.8 million in 2025, then fell by 8.16% to $61.4 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Operating Leases are $61.4 million (Q1 2026), $66.8 million (Q4 2025), and $70.6 million (Q3 2025).